[Intravesical hyaluronic acid in interstitial cystitis/painful bladder syndrome]
Donato M, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A.
Record ID 32018001408
Spanish
Original Title:
Ácido hialurónico intravesical en síndrome de vejiga dolorosa / cistitis intersticial
Authors' recommendations:
CONCLUSIONS
Moderate-quality evidence suggests that intravesical hyaluronic acid might reduce symptoms and would improve the quality of life in patients with diagnosed interstitial cystitis/painful bladder syndrome.
The clinical practice guidelines consulted generally recommend its use only when no other more conservative treatment options are available.
Hyaluronic acid has been approved by ANMAT and is reimbursed by the Unified Reimbursement System for this indication. Hyaluronic acid is not included in the list of technologies approved by the United States Food and Drug Administration. It is marketed in Europe as a Class 3 device (CE Mark) and the United Kingdom includes it as a benefit with reimbursement. Of the rest of the coverage policies surveyed, none mention this technology.
Details
Project Status:
Completed
Year Published:
2017
URL for published report:
https://www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Cystitis, Interstitial
- Urinary Bladder
- Female
- Hyaluronic Acid
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.